Shares of Intercept Pharmaceuticals (ICPT) are up 9.30% at $216.30, after the development stage biopharmaceutical company was defended at Oppenheimer. The firm’s analysts, who have $499 price target on the name, said in a report this morning that ICPT’s recent weakness does not appear tied to any new fundamental developments ; instead, they believe the […]
View the full post at: Front Runners: Intercept Pharmaceuticals (ICPT), Baidu (BIDU), Allied Healthcare Products (AHPI), NewLink Genetics (NLNK)